Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults

Allogeneic hematopoietic stem cell transplantation (HCT) remains the best established curative treatment for high-risk hematologic malignancies. Common indications for HCT, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), are largely diseases of older age and have poor outcomes after nontransplant therapy [1,2]. The feasibility of HCT after reduced-intensity conditioning (RIC) from HLA-matched related (MRD) or unrelated donor (MUD) has been well established, permitting overall survival (OS) of around 30% to 50% [3,4].

Source: Biology of Blood and Marrow Transplantation - December 27, 2017 Category: Hematology Authors: Stephanie B. Tsai, Joanna Rhodes, Hongtao Liu, Tsiporah Shore, Michael Bishop, Melissa M. Cushing, Usama Gergis, Lucy Godley, Justin Kline, Richard A. Larson, Sebastian Mayer, Olatoyosi Odenike, Wendy Stock, Amittha Wickrema, Koen van Besien, Andrew S. Ar Source Type: research